Wolfgang Hiddemann

LMU Klinikum — Germany

Medicine · Health Sciences

49h-index10.5kcitations308works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(131), Acute Lymphoblastic Leukemia research(59), Chronic Myeloid Leukemia Treatments(50), Palliative Care and End-of-Life Issues(34), Chronic Lymphocytic Leukemia Research(33)

Publications308 total

A platform of robust patient-derived leukemia models covering subgroups for which no cell lines exist
2025Open Access
Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia
Leukemia·2025Open Access
Prognosis and quality of life in patients with locally advanced rectal cancer after abdominoperineal resection in the CAO/ARO/AIO-04 randomized phase 3 trial
Scientific Reports·2025· 3 citedOpen Access
Hämatologie und Onkologie – Ein Rückblick auf 150 Jahre
DMW - Deutsche Medizinische Wochenschrift·2024
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
Communications Medicine·2023· 17 citedOpen Access
Supplementary Tables S1-4, Figures S1-6 from Modeling the Pharmacodynamics of Highly Schedule-Dependent Agents: Exemplified by Cytarabine-Based Regimens in Acute Myeloid Leukemia
2023Open Access
Data from CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes
2023Open Access
Data from Modeling the Pharmacodynamics of Highly Schedule-Dependent Agents: Exemplified by Cytarabine-Based Regimens in Acute Myeloid Leukemia
2023Open Access
Supplementary Figures S1-S3 from Transformation by Oncogenic Mutants and Ligand-Dependent Activation of FLT3 Wild-type Requires the Tyrosine Residues 589 and 591
2023Open Access
Data from CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes
2023Open Access
Ganzheitliche Begleitung von Krebspatienten
Die Innere Medizin·2023Open Access
Secondary Neoplasms in AML Long-Term Survivors: Even More Cancer to Come?
Blood·2022
Life Satisfaction and Quality of Life in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study
Blood·2022
German AMLCG-Survivorship Study: Anxiety and Depression Symptoms in AML Long-Term Survivors
Blood·2022
LIFETIME CLOSE TO THE END: EFFECTS ON PERCEIVED TIME AND AGING IN OLDER ADULTS WITH ADVANCED CANCER
Innovation in Aging·2022Open Access
Akute Myeloische Leukämien – Update 2022
DMW - Deutsche Medizinische Wochenschrift·2022· 2 cited
Experience of Time and Subjective Age When Facing a Limited Lifetime: The Case of Older Adults with Advanced Cancer
Journal of Aging and Health·2021· 7 citedOpen Access
Quality of Life and Life Satisfaction in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study
Blood·2021· 3 cited
High Prevalence of CHF and Diabetes in AML Long-Term Survivors - a Patient Forever?
Blood·2021· 2 cited
“Often Relatives are the Key […]” –Family Involvement in Treatment Decision Making in Patients with Advanced Cancer Near the End of Life
The Oncologist·2020· 36 citedOpen Access
page 1 of 16Next →

Frequent Co-authors

Karsten Spiekermann(15), Susanne Schnittger(9), Stefan K. Bohlander(9), Claudia Schoch(8), Wolfgang Kern(7), Torsten Haferlach(7), Tobias Herold(6), Stephanie Schneider(5), Eva C. Winkler(5), Thomas Büchner(4), Klaus H. Metzeler(4), Marion Subklewe(4), Evelyn Zellmeier(4), Bernhard Wörmann(4), Michael Kneba(4), Michaela Feuring‐Buske(4), Stella Reiter-Theil(4), Alfred Reiter(3), Martin Schrappe(3), WD Ludwig(3)